Dec 2017: A study performed by Schneider et. al. at OncoRay – National Center for Radiation Research in Oncology, Germany concluded that: “BioXmark has beneficial MRI properties regarding the trade-off between potential visibility and artifacts compared to the tested solid gold markers [Visicoil™ and GoldAnchor™] that are currently being used for IGRT of pancreatic ductal adenocarcinoma. Contrary to the solid markers, an increase in visibility of BioXmark was not directly coupled to an increase in artifact. BioXmark behaves comparably in all pulse sequences if acquired at similar resolution. The marker is also independent of its orientation in respect to the static magnetic field. The volume of marker material to be injected should, however, be considered and adapted to the resolution of the MRI protocol as its visibility can only be guaranteed if the marker is larger than the acquired voxel size. For a typical clinically achievable resolution in the abdominal region (typically ~3.5 mm³), a marker size of at least 25 uL (Ø 3.6 mm) is therefore advised”.